What question did this study set out to answer?

To assess thrombotic risk and pregnancy outcomes in patients with myeloproliferative neoplasms (MPNs) during pregnancy.

December 8, 2025BloodOpen Access

Distinctive features of patients with MPN during pregnancy: Thrombotic risk, molecular drivers, and differential outcomes by subtype

View Full Paper

Ask AI

Bookmark

To assess thrombotic risk and pregnancy outcomes in patients with myeloproliferative neoplasms (MPNs) during pregnancy.
Analyzed pregnancy outcomes in women with Ph-negative MPNs treated at a single center from 2014-2024.
Focused on risk factors such as thrombotic risk, genetic mutations, and maternal-fetal complications.
Utilized R-IPSET and Marchioli scores for thrombotic risk assessment, along with genetic analysis for mutations.
110 patients with MPN had 150 pregnancies, revealing significant adverse pregnancy outcomes.
ET patients had a lower loss rate (15.7%) and higher live birth rate (80.2%) compared to PV (36% loss, 51% live) and PMF (37.5% loss, 54.1% live).
Common complications included preterm birth (14%) and first-trimester miscarriage risk (16%).

No takes yet. Share an insight, caveat, or question.

Analysis reveals thrombotic risk relates to pregnancy outcomes in polycythemia vera, suggesting need for tailored management strategies.

Melikyan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark